NCT03784222

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 102 (actual)
• Sponsor: Sumitomo Pharma (Suzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is an open label, multi-center study to explore the effects on social functions of blonanserin in first episode schizophrenia patients

Conditions

• First Episode Schizophrenia
• Social Function
• Cognition Function
• Blonanserin

Interventions

Type	Name	Description
DRUG	Blonanserin	patients were prescribed blonanserin 4-24mg/d according to the patients' response and tolerability
OTHER	MRI and serum BDNF	60 patients receive MRI and serum BDNF test, 60 controls receive MRI, 20 of the 60 controls receive serum BDNF test

Timeline

• Start date: 2019-01-22
• Primary completion: 2022-11-22
• Completion: 2022-11-22
• First posted: 2018-12-21
• Last updated: 2024-04-19

Locations

8 sites across 1 country: China